Equity Profile

TECH

Bio-Techne Corporation

Health CareLife Sciences Tools & Services$11.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ4-2026Pre-Market9:00 AM EDT

Company Snapshot

Bio-Techne Corporation operates in the health care sector, focusing on life sciences tools and services. The company provides essential products and services that support research and clinical diagnostics, making it a key player in advancing health care solutions.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and will indicate how well Bio-Techne is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to assess the company's market demand and overall business health, particularly in the competitive life sciences sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TECH Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

In Q3-2026, Bio-Techne reported an EPS of $0.53, surpassing estimates by 11.11%. However, the stock fell by 16.36% the following day, indicating market disappointment despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Bio-Techne's upcoming earnings are uncertain due to mixed signals from previous quarters and lack of analyst estimates.

Bull Case

If the company continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially leading to a stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining revenue growth, it could lead to further stock price declines, especially given the recent volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and will it continue the trend of beating estimates?

Given the company's history of exceeding EPS expectations, this figure will be crucial for investor sentiment and stock performance.

How is revenue growth trending in comparison to previous quarters?

Revenue growth is essential for assessing the company's market position and ability to sustain profitability in a competitive environment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Techne's ability to sustain its earnings growth despite recent market volatility, as the company has consistently beaten EPS estimates.

Supporting Evidence

The company has a 100% EPS beat rate in the last 8 quarters, indicating strong operational performance.

Options pricing suggests a significant move, reflecting investor uncertainty that could lead to a larger reaction than expected.

Key Risk

If the EPS comes in above $0.55, it could challenge the cautious sentiment and shift investor outlook positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Bio-Techne's ability to maintain its earnings momentum amid competitive pressures and economic uncertainties.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.50 would confirm the bear case, indicating potential issues with profitability or revenue generation.

Pre-Earnings Positioning

Options Market

Implied Move

±30.67%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating either strong performance or notable challenges ahead.

Options are pricing ±30.7% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

80.0%

Calls (15K)P/C Ratio: 0.01Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests a potential stock increase of around 6.25%, reinforcing confidence in the company's growth strategy.

In-Line / Cautious

If results come in line with expectations, the stock may experience muted movement as investors await further guidance from management.

Miss

Should the company miss expectations, history indicates a potential decline of around 1.90%, raising concerns about future performance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the life sciences space.
2Management's commentary on revenue growth trends and market demand.
3Insights into cost management and gross margin expectations.
4Any guidance on future quarters and strategic initiatives.
5Responses to competitive pressures in the life sciences industry.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and will indicate how well Bio-Techne is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to assess the company's market demand and overall business health, particularly in the competitive life sciences sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TECH Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

In Q3-2026, Bio-Techne reported an EPS of $0.53, surpassing estimates by 11.11%. However, the stock fell by 16.36% the following day, indicating market disappointment despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Bio-Techne's upcoming earnings are uncertain due to mixed signals from previous quarters and lack of analyst estimates.

Bull Case

If the company continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially leading to a stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining revenue growth, it could lead to further stock price declines, especially given the recent volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and will it continue the trend of beating estimates?

Given the company's history of exceeding EPS expectations, this figure will be crucial for investor sentiment and stock performance.

How is revenue growth trending in comparison to previous quarters?

Revenue growth is essential for assessing the company's market position and ability to sustain profitability in a competitive environment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Techne's ability to sustain its earnings growth despite recent market volatility, as the company has consistently beaten EPS estimates.

Supporting Evidence

The company has a 100% EPS beat rate in the last 8 quarters, indicating strong operational performance.

Options pricing suggests a significant move, reflecting investor uncertainty that could lead to a larger reaction than expected.

Key Risk

If the EPS comes in above $0.55, it could challenge the cautious sentiment and shift investor outlook positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Bio-Techne's ability to maintain its earnings momentum amid competitive pressures and economic uncertainties.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.50 would confirm the bear case, indicating potential issues with profitability or revenue generation.

Pre-Earnings Positioning

Options Market

Implied Move

±30.67%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating either strong performance or notable challenges ahead.

Options are pricing ±30.7% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

80.0%

Calls (15K)P/C Ratio: 0.01Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests a potential stock increase of around 6.25%, reinforcing confidence in the company's growth strategy.

In-Line / Cautious

If results come in line with expectations, the stock may experience muted movement as investors await further guidance from management.

Miss

Should the company miss expectations, history indicates a potential decline of around 1.90%, raising concerns about future performance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the life sciences space.
2Management's commentary on revenue growth trends and market demand.
3Insights into cost management and gross margin expectations.
4Any guidance on future quarters and strategic initiatives.
5Responses to competitive pressures in the life sciences industry.